Literature DB >> 29153585

Identify the susceptibility profile to measles in the general population: Serological survey of measles antibodies in Shaanxi province, China, in 2016.

Lin Pei1, Yuxuan Yang2, Xiaodan Zhao2, Shaobai Zhang3, Lingyun Yuan4, Yamei Liu5, Yan Yu6.   

Abstract

The reported coverage with two doses of the measles vaccine (MCV) in Shaanxi Province, China, is greater than 95%, but the measles incidence over the whole province remains high. Cross-sectional serological surveys of measles antibodies in Shaanxi Province were conducted in 2016 to assess the population's immunity. The measles IgG levels were measured in serum samples using ELISA. The geometric means concentration (GMC) levels and seroprevalence rates with 95% CIs were calculated by region, gender, and age. A total of 3574 serum samples were collected from participants aged from 2 months to 49 years. The GMC of measles antibodies was 471.3 mIU/ml (95% CI: 445.9-498.2 mIU/ml), and the seroprevalence was only 85.9% (95% CI: 84.8-87.1%). A significant difference in the GMC (P < .05) but not the seroprevalence (P > .05) was observed among the 3 regions. The report measles incidences were high in individuals aged 0-7 months (33.2/100 000) and 8-17 months (26.8/100 000). Although both measles immunity (90.7%) and MCV coverage (89.7%) were low in children aged 8-17 months, the measles seroprevalence in adults was high at greater than 90%. These results revealed that further actions may be taken to increase vaccination coverage in children aged 8 months to 5 years over the whole province and teenagers in the south region. In particular, timely administration of the first MCV dose should be emphasized to prevent measles epidemics in children aged 8-17 months. Vaccination strategies may be varied by age and region.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antibody; Immunity; Measles elimination; Seroprevalence

Mesh:

Substances:

Year:  2017        PMID: 29153585     DOI: 10.1016/j.vaccine.2017.11.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018 - 2019 outbreak.

Authors:  Ravit Bassal; Victoria Indenbaum; Rakefet Pando; Tal Levin; Eilat Shinar; Doron Amichay; Mira Barak; Anat Ben-Dor; Adina Bar Haim; Ella Mendelson; Dani Cohen; Tamy Shohat
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

2.  Antibodies against measles and rubella virus among different age groups in Thailand: A population-based serological survey.

Authors:  Nasamon Wanlapakorn; Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Chompoonut Auphimai; Pornsak Yoocharoen; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2019-11-26       Impact factor: 3.240

3.  Prevalence of measles antibodies among migrant workers in Singapore: a serological study to identify susceptible population subgroups.

Authors:  Li Wei Ang; Qi Gao; Vernon Jian Ming Lee; Yee Sin Leo; Lin Cui; Aysha Farwin; Matthias Paul Han Sim Toh; Irving Charles Boudville; Mark I-Cheng Chen; Angela Chow; Raymond Tzer-Pin Lin
Journal:  BMC Infect Dis       Date:  2022-01-25       Impact factor: 3.090

4.  Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination.

Authors:  Chung-Jong Kim; Ji-Yun Bae; Kang-Il Jun; Hae-Sun Chung; Aeyeon Kim; Jihee Kim; Hee-Jung Son; Miae Lee; Hee-Jung Choi
Journal:  Vaccines (Basel)       Date:  2021-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.